Grace Therapeutics GRCE
NASDAQ GRCE
$2.00 +0.02 (+1.01%)
As of: Oct 21, 2026 · 3:39 PM EDT

Grace Therapeutics (GRCE) Convertible Debt (2019 - 2020)

Updated

Grace Therapeutics' Convertible Debt came in at $187,000 for fiscal Q4 2020 (quarter ended Mar 31, 2020), down 88.2% from $1.58 million a year earlier.

Analysis

Grace Therapeutics (GRCE) Convertible Debt (2019 - 2020) Analysis & Trends

  • Going back by fiscal year, Convertible Debt was $1.58 million in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,138.33 Bn 1,106.91 Bn 19.71 Bn
2 Johnson & Johnson 618.82 Bn 537.35 Bn 17.26 Bn
3 AbbVie 503.36 Bn 476.47 Bn 12.70 Bn
4 Merck 369.59 Bn 323.96 Bn 12.21 Bn
5 Novartis Ag 298.57 Bn 262.56 Bn 11.24 Bn
6 Astrazeneca 261.25 Bn 234.94 Bn 12.86 Bn
7 Amgen 237.35 Bn 192.75 Bn 7.24 Bn
8 Gilead Sciences 191.27 Bn 165.47 Bn 6.22 Bn
9 Pfizer 170.03 Bn 116.68 Bn 10.94 Bn
10 Grace Therapeutics 34.54 Mn -31.73 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2020 187,000.00
Mar 31, 2019 1.58 Mn
API Access

Grace Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=GRCE&period=max&api_key=YOUR_API_KEY